We headed to Newport Beach, California, for a State of the Science Summit on Gastrointestinal Cancers, which focused on the evolving paradigms of colorectal cancer, pancreatic cancer, neuroendocrine tumors, gastric cancer, and hepatocellular carcinoma.
Recently approved therapy is administered through program at New Jersey’s Only National Cancer Institute-designated Comprehensive Cancer Center.
Rutgers Cancer Institute investigator was awarded a grant to identify new treatment approaches in non–small cell lung cancer.
Jeffrey C. Lombardo, PharmD, BCOP, discusses the potential impact that ready-to-use formats for cytotoxic drugs might have in the oncology arena.
We visited Summit, New Jersey for a State of the Science Summit on non–small cell lung cancer (NSCLC). The meeting covered the current standard of care for early-stage lung cancer, approaches to locoregionally advanced NSCLC, updates in EGFR-positive NSCLC, and more.
ASCO and the entire oncology community are deeply saddened by the loss of colleague, friend, ASCO Board of Directors member, and geriatric oncology leader Arti Hurria, MD, FASCO.
The 2018 ESMO Congress brought us all the way to Munich, Germany. At this annual congress, data across various tumor types were presented, including genitourinary malignancies, breast cancer, head and neck squamous cell carcinoma, melanoma, gastrointestinal malignancies, and lung cancer.
We traveled to Cleveland, Ohio for a State of the Science Summit on Hematologic Malignancies. The meeting covered the evolving paradigm of chronic lymphocytic leukemia, updates in mantle cell lymphoma, treatment options for patients with newly diagnosed and relapsed/refractory multiple myeloma, unmet needs in myeloproliferative neoplasms, interesting genomic research in acute myeloid leukemia, and the challenges with treating patients with myelodysplastic syndrome.
Michael A. Caligiuri, MD, president of City of Hope National Medical Center, and Deana and Steve Campbell Physician-in-Chief Distinguished Chair, has been elected to the National Academy of Medicine, one of the highest honors in the fields of health and medicine.
Asian patients with untreated ALK-positive advanced NSCLC lived significantly longer without disease progression if they received the next-generation tyrosine kinase inhibitor alectinib instead of crizotinib as initial therapy.
Long-term follow-up from the COMBI-AD trial continued to show a significant relapse-free survival advantage for patients with resected stage III BRAF-mutant melanoma treated with adjuvant dabrafenib plus trametinib.
More than half of patients with advanced solid tumors associated with NTRK gene fusions responded to treatment with the small-molecule inhibitor entrectinib, an integrated analysis of 3 clinical trials showed.
Patients with advanced cancers associated with NTRK gene fusions had an 80% objective response rate with the TRK inhibitor larotrectinib, pooled results from three small trials showed.
Genetically engineered T-cells targeting a common tumor antigen appeared safe and demonstrated some evidence of antitumor activity in a first-in-human clinical evaluation.
Distinct gene signatures in renal cell carcinoma correlated with improved progression-free survival with immunotherapy or a targeted agent, according to a new analysis of the phase III IMmotion151 trial.
We returned to San Francisco, California for a State of the Science Summit on Breast Cancer. The meeting covered the use of CDK4/6 inhibitors in metastatic hormone receptor-positive breast cancer, adjuvant and neoadjuvant HER2-targeted therapy in early-stage HER2-positive disease, immunotherapy in triple-negative disease, and more.
We visited San Francisco, California for a State of the Science Summit on Hematologic Malignancies. The meeting covered novel agents and combinations in lymphoma, updates in acute and chronic leukemias, and modalities in the management of multiple myeloma.
Gene expression-based biomarkers associated with disease recurrence in patients with cutaneous squamous cell carcinoma may help in identifying a population subset considered to have high-risk disease.
The US Oncology Network has announced the results of the 2017 Merit-based Incentive Payment System for its affiliated practices.
We visited Chicago, Illinois for a State of the Science Summit on Renal Cell Carcinoma and Bladder Cancer. The meeting covered the genomics of bladder cancer, novel approaches to non-muscle invasive bladder cancer, side effect management from immunotherapy, as well as the integration of immunotherapy, chemotherapy, and targeted therapy in genitourinary cancers.
Physicians at the John Theurer Cancer Center at Hackensack Meridian Health Hackensack University Medical Center have enrolled the first two patients nationwide in an international phase II clinical trial of Kazia Therapeutics's novel therapy, GDC-0084, for glioblastoma.
B-cell malignancies are a heterogeneous subset of non-Hodgkin lymphomas in which treatment has remained essentially unchanged for the past 3 decades.
Nathan H. Fowler, MD, discusses the use of BTK inhibitors in B-cell malignancies.
Among the many new developments in B-cell lymphoma in recent years, the inhibition of Bruton tyrosine kinase represents a particularly notable achievement.
We traveled to Seattle, Washington for another State of the Science Summit on Hematologic Malignancies with faculty of Seattle Cancer Care Alliance and Fred Hutchinson Cancer Research Center. The meeting covered the latest updates in Hodgkin lymphoma, mantle cell lymphoma, multiple myeloma, and more.
Feinstein Institute for Medical Research Assistant Professor Catherine Benedict, PhD, has been awarded a 5-year, $693,000 grant from the National Institutes of Health to develop and test a digital health platform to help young female cancer survivors evaluate their options for having children, make decisions and plan for the future.
Urologists at Northwell Health’s Smith Institute for Urology recently started offering a new biopsy procedure which samples tissue from the prostate to potentially detect cancer – and eliminates the risk of infection.
We visited Dearborn, Michigan for a State of the Science Summit on Hematologic Malignancies with faculty of Karmanos Cancer Institute.